GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Total Long-Term Liabilities

Apollon Formularies (AQSE:APOL) Total Long-Term Liabilities : £0.00 Mil (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Apollon Formularies's Total Long-Term Liabilities for the quarter that ended in Jun. 2023 was £0.00 Mil.


Apollon Formularies Total Long-Term Liabilities Historical Data

The historical data trend for Apollon Formularies's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Total Long-Term Liabilities Chart

Apollon Formularies Annual Data
Trend Jun10 Jun11 Dec12 Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Apollon Formularies Semi-Annual Data
Jun11 Jun12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Jun23
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Apollon Formularies Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.


Apollon Formularies Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

Sobering Findings About Student Debt

By OPM Insights Nelson Hsu 11-07-2015

FPA Capital Fund Comments on Apollo Education Group Inc

By Vera Yuan Vera Yuan 05-22-2015

6 Highly Predictable Companies with Historically Low P/S Ratios

By Dianne Tordillo Dianne Tordillo 11-27-2012

The Yacktman Focused Fund's Top Growth Stocks

By Dianne Tordillo Dianne Tordillo 01-25-2013

FPA Capital Comments on Apollo Education

By Holly LaFon Holly LaFon 01-30-2017

FPA Capital Fund Comments on Apollo Education Group Inc

By Vera Yuan Vera Yuan 02-19-2015

Weekly Guru Bargains Highlights: APOL, GNW, BTU, NIHD, OKE

By GuruFocus GuruFocus 06-30-2012

Valuing Donald Yacktman's Portfolio: The Peter Lynch Fair Value

By Holly LaFon Holly LaFon 07-02-2012

Apollo Education Group Is a Value Trap

By OPM Insights Nelson Hsu 10-15-2015

Yacktman Fund Comments on Apollo

By Holly LaFon Holly LaFon 02-05-2016